Related Experiment Video

Updated: May 17, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

New anticoagulants for treatment of venous thromboembolism

Massimo Franchini1, Pier Mannuccio Mannucci

  • 1Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova, Italy.

European Journal of Internal Medicine
|October 26, 2012
PubMed

Insights

New anticoagulants offer alternatives for treating venous thromboembolism (VTE), addressing limitations of traditional therapies like heparins and vitamin K antagonists. Direct factor Xa and thrombin inhibitors show promise in VTE management.

Area of Science:

  • Cardiology
  • Hematology
  • Pharmacology

Background:

  • Venous thromboembolism (VTE) significantly contributes to patient morbidity and mortality.
  • Anticoagulation is the primary treatment for VTE.
  • Traditional anticoagulants (heparins, vitamin K antagonists) have limitations and unmet needs.

Purpose of the Study:

  • To summarize the characteristics of novel anticoagulant drugs.
  • To review the main results of clinical studies on VTE treatment with new agents.
  • To provide a critical overview of direct factor Xa inhibitors and direct thrombin inhibitors for VTE.

Main Methods:

  • Literature review of published clinical studies on VTE treatment.
  • Critical summary of characteristics of new anticoagulant drugs.
  • Analysis of efficacy and safety data for novel oral anticoagulants (NOACs).

Main Results:

  • Direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) and direct thrombin inhibitors (dabigatran etexilate) represent new therapeutic options.
  • These novel agents offer different pharmacokinetic and pharmacodynamic profiles compared to traditional anticoagulants.
  • Published clinical trials demonstrate the efficacy and safety of these new drugs in VTE treatment.

Conclusions:

  • Novel oral anticoagulants provide effective and safer alternatives for VTE treatment.
  • The development of direct oral anticoagulants addresses unmet needs in anticoagulation therapy.
  • These agents are poised to become integral components of VTE management strategies.

More Related Videos

Rodent Inferior Vena Cava Venoplasty Balloon Model05:44

Rodent Inferior Vena Cava Venoplasty Balloon Model

Published on: May 24, 2024

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...